Mydecine Innovations Group’s Director, CEO & Co-Founder, Joshua Bartch chats with our Director of Content, Jill Ettinger.
Similar Posts
Interview with Awais Spall, Functional Diagnostic Nutrition Practitioner at Integrative Oasis
In this conversation, we discuss some critical points such as how he managed to heal himself through the use of Ayurveda and functional medicine which led him down the path to working with these interesting modalities, how ancestral healing has the ability to significantly influence an individual’s wellbeing overall, how his practice uses entheogens to cure physical ailments such as Traumatic Brain Injury, and more!
Red Light Holland CANNABIS Merger, Atai IPO, NUMI Uplists, MindMed & More (TRUFF, atai, Numi, MMED)
LOTS of news happened this week, one of the major ones being Red Light Holland’s merger with a CANNABIS Company called Cresco. Other news we discuss in today’s segment is atai Life Sciences Nasdaq uplisting, MindMed’s new addition to the team, Numinus’ Uplisting and Field Trip’s upcoming financial results.
Enjoy!
Timestamps:
0:00 – Intro
1:00 – atai Life Sciences Nasdaq IPO
2:56 -Red Light Holland Merging With A Cannabis Company & Acquisition
7:26 -Numinus Wellness Uplists To The TSX
8:45 – MindMed Appoints Peter Bergethon To Their Scientific Advisory Board
10:36 – Field Trip’s Upcoming Financial Results
Links:
atai Life Sciences ( NASDAQ: atai)
https://www.cnbc.com/2021/06/18/peter-thiel-backed-psychedelic-start-ups-shares-pop-in-wall-street-debut.html
Red Light Holland ( CSE: TRIP / OTC: TRUFF) Closes Acquisition of 80% of Happy Caps Mushroom Farm:
https://ca.finance.yahoo.com/news/red-light-holland-closes-acquisition-122000805.html
Red Light Holland is Merging with a Cannabis company called Creso Pharma to create The HighBrid Lab:
https://www.newsfilecorp.com/release/87740/Creso-Pharma-and-Red-Light-Holland-Merge-to-Introduce-The-HighBrid-Lab-TM-a-Leading-Global-Psychedelics-x-Cannabis-Company-Specializing-in-Recreational-Products-Applied-Science-Technology-and-Innovation
Numinus Wellness (OTC: LKYSF, TSX.V: NUMI) Uplists to Tier 1 on the TSX Venture Exchange:
https://thecannabisstock.com/2021/06/18/numinus-wellness-gradu
MindMed (NASDAQ: MNMD, NEO: MMED) Appoints Pharmaceutical Veteran, DR Peter Bergethon to their Scientific Advisory Board:
https://www.prnewswire.com/news-releases/mindmed-appoints-pharmaceutical-veteran-peter-bergethon-md-to-scientific-advisory-board-301314501.html
Field Trip Health (OTC: FTRPF, TSX: FTRP) Will Release Financial Results for its fiscal fourth quarter and full year 2021 ended March 31, 2021:
https://ca.movies.yahoo.com/field-trip-health-ltd-announces-131000469.html
https://www.meetfieldtrip.com/news/news-details/2021/Field-Trip-Health-Ltd.-Schedules-Fiscal-Fourth-Quarter-and-Full-Year-2021-Financial-Results-Conference-Call-for-Friday-June-25-2021-At-800-am-ET/default.aspx
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
editing:@themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#RedLightHolland #MindMed #atai
MindMed CEO AMA: 18-MC Patent, Digital Tech, LSD Trials and More! (MNMD / MMED)
In today’s episode, James from PSYCBiz interviews Robert Barrow, CEO…
Psychedelic Spotlight Interview with David Champion
In this episode of the Psychedelic Spotlight podcast, we speak…
Psychedelic Stocks in the Short-Term: Expectations, Catalysts, Risks and Reward
When it comes to investing in psychedelic stocks such as MindMed (MNMD, MMED), Compass Pathways (CMPS), atai Life Sciences (ATAI), Cybin (CYBN) and more, even if we have a solid long term thesis, the short term is very volatile.
To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
PS: THIS IS NOT INVESTING ADVICE, JUST MY OPINION.
In this video, I will discuss what to look out for, both the positives and the negatives, in the coming months. What are the catalysts? What are the risks?
The main thing to understand, is that the market cares more about short term profit than it does long term indicators. Right now, we are seeing psychedelic medicine clinical trials showing fantastic results, but we should not expect the market to react until we are closer to commercialization.
There are also many macro risks to be aware of, and general all around volatility. But we need to remember, short term swings do not affect the long-term thesis.
Links:
Awakn Phase 2 Ketamine Therapy for Alcohol Use Disorder:
https://psychedelicspotlight.com/ketamine-trial-alcohol-use-disorder-promising-results-awakn-life-sciences/
MAPS Phase 3 MDMD for PTSD Trial
https://psychedelicspotlight.com/first-phase-3-trial-mdma-assisted-therapy-ptsd/
Compass Pathways Phase 2b Psilocybin for Depression Trial
https://psychedelicspotlight.com/compass-pathways-largest-psilocybin-therapy-trial-ever-depressive-symptoms-rapidly-reduce/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#PsychedelicStocks #MindMed #Cybin
MORE Companies to UPLIST On NASDAQ? Compass Pathways Trial Results & More (CMPS, FTRP, MYCO, CYBN) 🚀
Compass Pathways (CMPS:NASDAQ) published amazing COMP360 Psilocybin Study results that will serve as support for companies working with psilocybin and psilocybin derivatives. However, this isn’t the only news worth mentioning.
Field Trip Health (FTRP: CSE) and (FTRPF: OTC) recently uplisted on the TSX ( Toronto Stock Exchange) and has filed an application to uplist on the Nasdaq.
While this is great news for Field Trip, it is not the only company who has filed to uplist. Silo Pharma, (SILO: OTC), has also put in an application to list on NASDAQ.
MagicMed will also join the ranks, however it will be through an acquisition.
Moreover, Cybin (CYBN: NEO,) and (CLXPF: OTC), is working on a transportable, wearable, helmet that completes a brain scan, through a partnership with a company called Kernel.
There is also news on Mydecine ( MYCO: NEO) and ( MYCOF: OTC) and MindCure (CSE: MCUR) (OTCQB: MCURF), so stay tuned till the end!
Enjoy the episode!
Timestamps:
0:00 – Intro
0:51 – Compass Pathways COMP360 Study Results
3:37 – Cybin Ketamine Study
7:14- Field Trip Uplists on the TSX And Applies To List On The NASDAQ
11:10 – Silo Pharma Applies To Uplist on The NASDAQ
12:11 – MagicMed to List On NASDAQ Through Acquisition
15:16- Mydecine Expands Cultivation Capabilities for Psilocybin
17:32- MINDCURE Completes First Stage of Manufacturing Synthetic Ibogaine
Links:
Compass Pathways Study Results On The Safety And Cognitive Effects Of Taking a Dose Of Psilocybin COMP360:
https://www.globenewswire.com/news-release/2021/06/03/2241445/0/en/COMPASS-Pathways-and-Kings-College-London-publish-cognition-results-from-COMP360-psilocybin-study-in-healthy-volunteers.html
Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral Cortex Hemodynamics
https://psilocybinalpha.com/news/cybin-announces-sponsorship-of-a-kernel-flow-feasibility-study-to-measure-ketamines-psychedelic-effects-on-cerebral-cortex-hemodynamics
Field Trip Health Uplists on the TSX:
https://www.globenewswire.com/news-release/2021/06/03/2241200/0/en/Field-Trip-Health-Ltd-to-Commence-Trading-on-the-Toronto-Stock-Exchange-on-June-7-2021.html
FTRP Applies To Uplist On NASDAQ:
https://stockhouse.com/news/the-market-herald-news/2021/06/08/field-trip-health-tsx-ftrp-applies-to-list-on-nasdaq-stock-market
MagicMed Will Be Acquired by Nasdaq-listed Enveric Biosciences
https://psilocybinalpha.com/news/magicmed-to-be-acquired-by-nasdaq-listed-company
Health Canada Has Approved an Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms MYCO: NEO), (MYCOF: OTC) :
https://finance.yahoo.com/news/health-canada-approves-expansion-mydecine-113000924.html
MINDCURE, (CSE: MCUR) (OTCQB: MCURF), Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research:
https://www.prnewswire.com/news-releases/mindcure-successfully-completes-first-stage-of-manufacturing-synthetic-ibogaine-for-use-in-psychedelic-clinical-research-301304810.html
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
editing:@themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #Mydecine #FieldTrip